Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 4/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 5/20 | 0.39 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781181 | 1.00 | CLK1 (0.42) | CLK1MKNK1MKNK2CYP1A2SCN5A | |
| SCHEMBL19781539 | 0.91 | CLK1 (0.47) | CLK1MKNK1MKNK2CYP1A2SCN5A | |
| SCHEMBL24460223 | 0.90 | BCL2 (0.44) | CLK1MKNK1MKNK2CYP1A2SCN5A | |
| SCHEMBL19781168 | 0.90 | SCN5A (0.50) | CLK1MKNK1MKNK2CYP1A2SCN5A | |
| SCHEMBL19781553 | 0.90 | SCN5A (0.50) | CLK1MKNK1MKNK2CYP1A2SCN5A | |
| SCHEMBL19781775 | 0.88 | FLT3 (0.51) | CLK1MKNK1CYP1A2SCN5APIK3CA | |
| SCHEMBL19781776 | 0.85 | FYN (0.54) | CLK1MKNK1MKNK2CYP1A2PIK3CA | |
| SCHEMBL24460204 | 0.83 | FYN (0.54) | CLK1MKNK1MKNK2CYP1A2PIK3CA | |
| SCHEMBL24460322 | 0.83 | CLK1 (0.42) | CLK1MKNK1MKNK2CYP1A2SCN5A | |
| SCHEMBL24460271 | 0.83 | CLK1 (0.42) | CLK1MKNK1MKNK2CYP1A2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2022108849-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2020117794-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-10 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | HAVCR2, ZC3HAV1, CD4 | CLK1 4595/4885MKNK1 2116/4885MKNK2 2340/4885 |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | CLK1 3537/4885MKNK1 3245/4885MKNK2 3215/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | CLK1 3012/4885MKNK1 3509/4885MKNK2 3686/4885 |
| US-20190308938-A1 | Heterocyclic Compounds for the Treatment of Arenavirus | C9, C1R, C1S | CLK1 3012/4885MKNK1 3509/4885MKNK2 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.